ArticleCureus2026
Identification and Molecular Characterization of Non-fermenting Gram-Negative Bacilli Exhibiting Carbapenem Resistance Isolated From Various Clinical Specimens in a Tertiary Care Hospital.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNon-fermenting Gram-negative bacilli (NFGNB), including
methodsA descriptive and retrospective study was conducted in the Department of Microbiology, Government Doon Medical College, Dehradun, India, from September 2020 to February 2022. A total of 3,235 clinical specimens were processed for culture and identification. NFGNB were identified by colony morphology, Gram-staining, and biochemical tests. Antimicrobial susceptibility was performed using the Kirby-Bauer disc diffusion method. Screening for carbapenem resistance was done using imipenem and meropenem antibiotic discs, and MBL production was confirmed by the combined disc test (CDT) and modified Hodge test (MHT). Polymerase chain reaction (PCR) was used to detect
resultsAmong 3,235 clinical samples, 1,924 (59.47%) samples showed culture positivity. A total of 220 (25.82%) isolates of NFGNB out of 852 (44.28%) isolates of Gram-negative bacilli were observed. The maximum proportion of NFGNB, excluding Gram-negative bacilli isolates, was reported from the pus (95, 89.62%) sample.
conclusionThe high prevalence of carbapenem-resistant and MBL-producing NFGNB underscores the urgent need for rapid detection, rational antibiotic use, and stringent infection control measures to limit the spread of multidrug-resistant organisms in healthcare settings.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.